• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Bausch & Lomb earns NTIOL status for two lens products

Article

Bausch & Lomb has earned NTIOL status for its SofPort Advanced Optics and SofPort Advanced Optics with Violet Shield lenses.

Key Points

Rochester, NY-The Centers for Medicare and Medicaid Services has granted new technology IOL (NTIOL) designation to two lenses (SofPort Advanced Optics and SofPort Advanced Optics with Violet Shield, Bausch & Lomb) for their spherical aberration-reducing design.

Based on this new designation, which was effective March 6, Medicare will increase by $50 its reimbursement to ambulatory surgery centers when cataract procedures are performed with either of these lenses.

The NTIOL designation and adjusted payment will remain in effect until Feb. 26, 2011.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
© 2024 MJH Life Sciences

All rights reserved.